Related content

A phase I clinical trial of low-dose interferon-α-2A, thalidomide plus gemcitabine and capecitabine for patients with progressive metastatic renal cell carcinoma

By Amato Robert   Khan Muhammad  

Cancer Chemotherapy and Pharmacology, Vol. 61, Iss. 6, 2008-05 ,pp. : 1069-1073

Springer Publishing Company

Access to resources Recommend Favorite

A phase I, pharmacokinetic and pharmacodynamic study of nimotuzumab in Japanese patients with advanced solid tumors

By Okamoto Wataru   Yoshino Takayuki   Takahashi Toshiaki   Okamoto Isamu   Ueda Shinya   Tsuya Asuka   Boku Narikazu   Nishio Kazuto   Fukuoka Masahiro   Yamamoto Nobuyuki   Nakagawa Kazuhiko  

Cancer Chemotherapy and Pharmacology, Vol. 72, Iss. 5, 2013-11 ,pp. : 1063-1071

Springer Publishing Company

Access to resources Recommend Favorite

Phase I dose escalation study of docetaxel with filgrastim support in patients with advanced solid tumors

By Masters Gregory   Brockstein Bruce   Mani Sridhar   Ratain Mark  

Medical Oncology, Vol. 20, Iss. 1, 2003-03 ,pp. : 7-12

Humana Press, Inc

Access to resources Recommend Favorite

Phase I dose-escalation study of a novel antitumor agent, SR271425, administered intravenously in split doses (d1–d2–d3) in patients with refractory solid tumors

By Campone M.   Isambert N.   Bourbouloux E.   Maury S.   Monin-Baroille P.   Berille J.   Fumoleau P.  

Cancer Chemotherapy and Pharmacology, Vol. 59, Iss. 5, 2007-04 ,pp. : 689-695

Springer Publishing Company

Access to resources Recommend Favorite

A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors

By Fury Matthew   Solit David   Su Yungpo   Rosen Neal   Sirotnak F.   Smith Robert   Azzoli Christopher   Gomez Jorge   Miller Vincent   Kris Mark   Pizzo Barbara   Henry Roxanne   Pfister David   Rizvi Naiyer  

Cancer Chemotherapy and Pharmacology, Vol. 59, Iss. 4, 2007-03 ,pp. : 467-475

Springer Publishing Company

Access to resources Recommend Favorite